<DOC>
	<DOCNO>NCT01486992</DOCNO>
	<brief_summary>There study 2nd line treatment advance esophageal carcinoma ( AEC ) , show irinotecan may effective . The investigator previous study show efficacy safety paclitaxel/cisplatin 1st line treatment , phase II study , investigator would like observe efficacy safety Nimotuzumab plus Irinotecan/5FU/leucovorin 2nd line treatment AEC failure 1st treatment PTX/DDP .</brief_summary>
	<brief_title>mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy Squamous-cell Carcinoma Esophagus</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Histologically confirm esophageal squamous carcinoma , fail 1st line treatment paclitaxel/cisplatin Age 18 75 year old Measurable disease accord RECIST criterion ( diameter lesion 10mm spiral CT MRI , 20mm common CT , date image le 15 day enrollment ) Life expectancy ≥3 month Karnofsky performance status ≥80 WBC &gt; 3,500/mm3 , absolute neutrophil count ≥2000/mm3 , platelet &gt; 100,000/mm3 , Hb &gt; 9g/dl，Bilirubin level &lt; 1.0 time ULN，Serum creatinine &lt; 1.0 time ULN，ALT AST &lt; 2.5 time ULN ，AKP &lt; 2.5 time ULN ， ( ≤5 time ULN patient liver metastasis ) ( within 7 day enrollment ) No sever complication , active gastrointestinal bleeding , perforation , jaundice , obstruction , noncancerous fever＞38℃； Normal ECG/cardiac function Good compliance Having sign informed consent More 1 Previous systemic therapy metastatic esophageal squamous carcinoma Known hypersensitivity study drug Tumor length≥10cm , liver metastasis cover 50 % liver , lung metastasis cover 25 % lung No measurable lesion , eg . pleural fluid ascites Only Other previous malignancy within 5 year , except nonmelanoma skin cancer Heart failure sever organ dysfunction , eg . coronary artery disease , myocardial infarction within last 6 month Brain bone metastasis Chronic diarrhea Mentally abnormal disable cognition , include CNS metastasis Pregnancy lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>